Advertisement
Advertisement
KYNB
Kyntra Bio, Inc. Common Stock
6.73
USDSponsored
-0.06
-0.88%
Jul 31, 15:59 UTC -4
Closed
After-Market
6.83
+0.09
+1.41%
KYNB Earnings Reports
Positive Surprise Ratio
KYNB beat 2 of 3 last estimates.
67%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$2.05M
/-$3.24
Implied change from Q1 26 (Revenue/ EPS)
-45.24%
/-13.83%
Implied change from Q2 25 (Revenue/ EPS)
--
/+72.34%
Kyntra Bio, Inc. Common Stock earnings per share and revenue
On May 11, 2026, KYNB reported earnings of -3.76 USD per share (EPS) for Q1 26, missing the estimate of -3.42 USD, resulting in a -9.87% surprise. Revenue reached 3.74 million, compared to an expected 1.34 million, with a 179.75% difference. The market reacted with a +6.25% price change (close before vs. close after earnings).
Looking ahead to Q2 26, -- analysts forecast an EPS of -3.24 USD, with revenue projected to reach 2.05 million USD, implying an decrease of -13.83% EPS, and decrease of -45.24% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
FibroBiologics, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$0.73
Actual
-$0.66
Surprise
+10.13%
Bristol-Myers Squibb Co.
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.60
Actual
$2.04
Surprise
+27.37%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Guardant Health, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.42
Surprise
-0.02%
Agios Pharmaceuticals, Inc.
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.70
Actual
-$1.69
Surprise
+0.66%
Vericel Corporation
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.02
Actual
$0.04
Surprise
+239.37%
Wave Life Sciences Ltd. Ordinary Shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.31
Actual
-$0.34
Surprise
-8.94%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Jul 30, 2026 For Q2 26
Estimate
$0.02
Actual
$0.02
Surprise
-0.50%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.25
Actual
$0.00
Surprise
+100.00%
Castle Biosciences, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.41
Actual
-$0.07
Surprise
+83.12%
FAQ
What were Kyntra Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Kyntra Bio, Inc. Common Stock reported EPS of -$3.76, missing estimates by -9.87%, and revenue of $3.74M, 179.75% above expectations.
How did the market react to Kyntra Bio, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 6.25%, changed from $6.80 before the earnings release to $7.22 the day after.
When is Kyntra Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Kyntra Bio, Inc. Common Stock's next earnings report?
Based on --
analysts, Kyntra Bio, Inc. Common Stock is expected to report EPS of -$3.24 and revenue of $2.05M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement